Molnupiravir Plus Usual Care Versus Usual Care Alone as Early Treatment for Adults with COVID-19 at Increased Risk of Adverse Outcomes (PANORAMIC): Preliminary Analysis from the United Kingdom Randomised, Controlled Open-Label, Platform Adaptive Trial

Butler C., Hobbs FDR., Gbinigie O., Rahman NM., Hayward G., Richards D., Dorward J., Lowe D., Standing JF., Breuer J., Khoo S., Petrou S., Hood K., Nguyen-Van-Tam JS., Patel M., Saville BR., Marion J., Ogburn E., Allen J., Rutter H., Francis N., Thomas N., Evans P., Dobson M., Madden T-A., Holmes J., Harris V., Png ME., Lown M., van Hecke O., Detry M., Saunders C., Fitzgerald M., Berry N., Mwandigha L., Galal U., Jani B., Hart N., Butler D., Chalk J., Lavallee L., Hadley E., Cureton L., Benysek M., Andersson M., Coates M., Barrett S., Bateman C., Davies J., Raymundo-Wood I., Ustianowski A., Carson-Stevens A., Yu L-M., Little P.

DOI

10.2139/ssrn.4237902

Type

Preprint

Publication Date

18/10/2022

Permalink Original publication